Incretins are “gut hormones that are secreted after food intake and play a role in modulating blood glucose by stimulating insulin secretion and suppressing appetite,”
Carmot Therapeutics' lead asset CT-388 is a Phase-II ready dual GLP-1/GIP agonist with best-in-class potential as a treatment for obesity in individuals with and without type 2 diabetes.
Assets
"We are encouraged by the clinical data for the lead asset CT-388, which demonstrated substantial weight loss in Phase Ib. These data suggest the potential for a differentiated profile to treat obesity and its associated diseases," shared Dr
Carmot's portfolio "offers different routes of administration and opportunities to develop combination therapies that treat obesity and potentially other indications,"
Additional clinical assets for obesity and diabetes
- CT-996, a daily oral, small molecule GLP-1 receptor agonist currently in Phase I is intended as an obesity treatment in patients with and without type 2 diabetes
- CT-868 is a Phase II-ready, once-daily subcutaneous injectable, dual GLP-1/GIP receptor agonist intended for treating type 1 diabetes patients who are overweight or obese.
Under the agreement,
The transaction is subject to certain customary closing conditions. The closing of the transaction is currently expected to occur in the first quarter of 2024.
NEWS:
The post
© Russell Publishing Limited, 2023. All Rights Reserved., source